JP2015523328A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015523328A5 JP2015523328A5 JP2015511443A JP2015511443A JP2015523328A5 JP 2015523328 A5 JP2015523328 A5 JP 2015523328A5 JP 2015511443 A JP2015511443 A JP 2015511443A JP 2015511443 A JP2015511443 A JP 2015511443A JP 2015523328 A5 JP2015523328 A5 JP 2015523328A5
- Authority
- JP
- Japan
- Prior art keywords
- ctla
- polypeptide
- amino acid
- acid sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 21
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 21
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 21
- 229920001184 polypeptide Polymers 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 238000000034 method Methods 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 2
- 102000054189 human CD80 Human genes 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 2
- 101000946850 Homo sapiens T-lymphocyte activation antigen CD86 Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 102000049849 human CD86 Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261645686P | 2012-05-11 | 2012-05-11 | |
| US61/645,686 | 2012-05-11 | ||
| PCT/US2013/030179 WO2013169338A1 (en) | 2012-05-11 | 2013-03-11 | Ctla-4 variants |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015523328A JP2015523328A (ja) | 2015-08-13 |
| JP2015523328A5 true JP2015523328A5 (enExample) | 2016-03-31 |
| JP6228971B2 JP6228971B2 (ja) | 2017-11-08 |
Family
ID=49551120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015511443A Active JP6228971B2 (ja) | 2012-05-11 | 2013-03-11 | Ｃｔｌａ−４バリアント |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9884902B2 (enExample) |
| EP (2) | EP2863936A4 (enExample) |
| JP (1) | JP6228971B2 (enExample) |
| KR (1) | KR102133060B1 (enExample) |
| CN (2) | CN107540742B (enExample) |
| AU (1) | AU2013260172B2 (enExample) |
| BR (1) | BR112014026718B1 (enExample) |
| CA (1) | CA2868748C (enExample) |
| DK (1) | DK3207938T3 (enExample) |
| ES (1) | ES2777778T3 (enExample) |
| HK (1) | HK1209644A1 (enExample) |
| HU (1) | HUE048925T2 (enExample) |
| MX (2) | MX355234B (enExample) |
| PL (1) | PL3207938T3 (enExample) |
| RU (1) | RU2671465C2 (enExample) |
| SG (2) | SG11201405968SA (enExample) |
| WO (1) | WO2013169338A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4119857A1 (de) | 1991-06-17 | 1992-12-24 | Basf Lacke & Farben | Ueberzugsmittel auf der basis von carboxylgruppenhaltigen polymeren und epoxidharzen |
| MX355234B (es) * | 2012-05-11 | 2018-04-11 | Medimmune Ltd | Variantes de antigeno 4 del linfocito t citotoxico (ctla-4). |
| WO2014004780A1 (en) * | 2012-06-29 | 2014-01-03 | Bristol-Myers Squibb Company | Methods for reducing glycoprotein aggregation |
| US9944689B2 (en) * | 2013-03-07 | 2018-04-17 | The General Hospital Corporation | Human CTLA4 mutants and use thereof |
| CN105916883B (zh) * | 2014-01-28 | 2019-12-03 | 北京韩美药品有限公司 | 双功能融合蛋白及其制备方法和用途 |
| WO2016115275A1 (en) | 2015-01-13 | 2016-07-21 | City Of Hope | Ctla4-binding protein peptide-linker masks |
| MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| SMT202100467T1 (it) | 2015-04-17 | 2021-09-14 | Alpine Immune Sciences Inc | Proteine immunomodulatorie con affinità regolabili |
| CN108137659B (zh) | 2015-08-21 | 2021-11-26 | 汉阳大学校产学协力团 | 具有预防或治疗中枢神经系统疾病作用的肽和包含其作为活性成分的药物组合物 |
| US11351224B2 (en) | 2015-08-21 | 2022-06-07 | Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) | Pharmaceutical composition for preventing and treating transplant rejection |
| WO2017034244A1 (ko) * | 2015-08-21 | 2017-03-02 | 한양대학교 산학협력단 | 중추신경계 질환에 대한 예방 또는 치료효과를 갖는 펩타이드 및 이를 유효성분으로 하는 중추신경계 질환 예방 및 치료용 약학적 조성물 |
| EP3350206A1 (en) * | 2015-09-14 | 2018-07-25 | Alpine Immune Sciences, Inc. | Tunable variant immunoglobulin superfamily domains and engineered cell therapy |
| CN108367069B (zh) | 2015-12-14 | 2022-08-23 | 宏观基因有限公司 | 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法 |
| KR101918456B1 (ko) * | 2015-12-15 | 2018-11-16 | 앱클론(주) | Cd80 및 cd86에 특이적으로 결합하는 항체 |
| SG11201808457PA (en) | 2016-04-15 | 2018-10-30 | Alpine Immune Sciences Inc | Icos ligand variant immunomodulatory proteins and uses thereof |
| AU2017248830B2 (en) | 2016-04-15 | 2023-03-09 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
| EP3491013A1 (en) | 2016-07-28 | 2019-06-05 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
| JP2020511144A (ja) | 2017-03-16 | 2020-04-16 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用 |
| MX2019010887A (es) | 2017-03-16 | 2019-10-15 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras de cb80 variante y usos de estas. |
| CN108948194B (zh) * | 2017-05-19 | 2023-02-17 | 上海药明生物技术有限公司 | 一种新的ctla-4单克隆抗体 |
| EP3630843A2 (en) | 2017-05-24 | 2020-04-08 | ALS Therapy Development Institute | Therapeutic anti-cd40 ligand antibodies |
| EP3694870A1 (en) * | 2017-10-10 | 2020-08-19 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
| JP7282760B2 (ja) | 2017-10-18 | 2023-05-29 | アルパイン イミューン サイエンシズ インコーポレイテッド | バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法 |
| SG11202006148UA (en) | 2018-01-03 | 2020-07-29 | Alpine Immune Sciences Inc | Multi-domain immunomodulatory proteins and methods of use thereof |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| CA3106384A1 (en) * | 2018-11-02 | 2020-05-07 | Beijing Vdjbio Co., Ltd. | Modified ctla4 and methods of use thereof |
| CN113727998A (zh) | 2018-11-30 | 2021-11-30 | 高山免疫科学股份有限公司 | Cd86变体免疫调节蛋白及其用途 |
| WO2020210596A1 (en) * | 2019-04-10 | 2020-10-15 | University Of Kentucky Research Foundation | Modified prostate apoptosis response-4 (par-4) polypeptide, and methods of production and use |
| CA3166299A1 (en) * | 2020-01-11 | 2021-07-15 | Paul STABACH | Compositions and methods for treating, ameliorating, and/or preventing diseases or disorders caused by or associated with dnase1 and/or dnase1l3 deficiency |
| WO2021195418A1 (en) | 2020-03-26 | 2021-09-30 | Vanderbilt University | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) |
| CA3171795A1 (en) * | 2020-04-06 | 2021-10-14 | Jintang DU | Modular synthetic receptors and methods of use |
| AU2021262609A1 (en) | 2020-05-01 | 2022-12-22 | Kashiv Biosciences, Llc | An improved process of purification of protein |
| US12202882B2 (en) | 2020-05-08 | 2025-01-21 | Alpine Immune Sciences, Inc. | APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof |
| CN112661865B (zh) * | 2020-12-31 | 2026-04-03 | 厚朴生物科技（苏州）有限公司 | 针对新型冠状病毒的疫苗以及其应用 |
| WO2023057994A1 (en) * | 2021-10-08 | 2023-04-13 | Kashiv Biosciences, Llc | Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography |
| AU2022361768A1 (en) * | 2021-10-08 | 2024-05-02 | Kashiv Biosciences, Llc | Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography |
| AU2022414315A1 (en) * | 2021-12-17 | 2024-07-25 | Kashiv Biosciences, Llc | An improved assay method for determining the potency of recombinant protein |
| TW202342510A (zh) | 2022-02-18 | 2023-11-01 | 英商Ｒｑ生物科技有限公司 | 抗體 |
| WO2024211211A1 (en) | 2023-04-03 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Methods of improving transplant survival using il-2 receptor gamma chain antibodies |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69226871T3 (de) | 1991-06-27 | 2009-09-24 | Bristol-Myers Squibb Co. | CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung |
| US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| WO1997047732A2 (en) * | 1996-06-14 | 1997-12-18 | Smithkline Beecham Corporation | Hexameric fusion proteins and uses therefor |
| TWI314933B (en) * | 2000-05-26 | 2009-09-21 | Bristol Myers Squibb Compan | Soluble ctla4 mutant molecules and uses thereof |
| US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| WO2007007654A1 (ja) | 2005-07-07 | 2007-01-18 | Toshiba Lighting & Technology Corporation | 放電灯点灯装置および電球形蛍光ランプ |
| GB0620934D0 (en) * | 2006-10-20 | 2006-11-29 | Cambridge Antibody Tech | Protein variants |
| CA2703263C (en) * | 2007-11-01 | 2014-03-18 | Perseid Therapeutics Llc | Immunosuppressive polypeptides and nucleic acids |
| EP3053932B1 (en) * | 2010-02-19 | 2020-07-22 | Xencor, Inc. | Novel ctla4-ig immunoadhesins |
| WO2011113019A2 (en) * | 2010-03-12 | 2011-09-15 | Abbott Biotherapeutics Corp. | Ctla4 proteins and their uses |
| MX355234B (es) * | 2012-05-11 | 2018-04-11 | Medimmune Ltd | Variantes de antigeno 4 del linfocito t citotoxico (ctla-4). |
-
2013
- 2013-03-11 MX MX2014013092A patent/MX355234B/es active IP Right Grant
- 2013-03-11 CA CA2868748A patent/CA2868748C/en active Active
- 2013-03-11 ES ES17163638T patent/ES2777778T3/es active Active
- 2013-03-11 SG SG11201405968SA patent/SG11201405968SA/en unknown
- 2013-03-11 CN CN201710735648.7A patent/CN107540742B/zh active Active
- 2013-03-11 PL PL17163638T patent/PL3207938T3/pl unknown
- 2013-03-11 RU RU2014150092A patent/RU2671465C2/ru active
- 2013-03-11 DK DK17163638.4T patent/DK3207938T3/da active
- 2013-03-11 WO PCT/US2013/030179 patent/WO2013169338A1/en not_active Ceased
- 2013-03-11 CN CN201380024763.3A patent/CN104302309B/zh active Active
- 2013-03-11 HK HK15110585.3A patent/HK1209644A1/xx unknown
- 2013-03-11 EP EP13787673.6A patent/EP2863936A4/en not_active Withdrawn
- 2013-03-11 AU AU2013260172A patent/AU2013260172B2/en active Active
- 2013-03-11 KR KR1020147031064A patent/KR102133060B1/ko active Active
- 2013-03-11 BR BR112014026718-9A patent/BR112014026718B1/pt active IP Right Grant
- 2013-03-11 MX MX2018003741A patent/MX385969B/es unknown
- 2013-03-11 JP JP2015511443A patent/JP6228971B2/ja active Active
- 2013-03-11 SG SG10201609447XA patent/SG10201609447XA/en unknown
- 2013-03-11 HU HUE17163638A patent/HUE048925T2/hu unknown
- 2013-03-11 US US14/399,685 patent/US9884902B2/en active Active
- 2013-03-11 EP EP17163638.4A patent/EP3207938B1/en active Active
-
2017
- 2017-12-21 US US15/850,990 patent/US20180208639A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tao et al. | Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines | |
| JP2011508604A5 (enExample) | ||
| Bermudez-Humaran et al. | An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci | |
| WO2009042570A3 (en) | Modified t cell receptors and related materials and methods | |
| JP2016532693A5 (enExample) | ||
| EP4647442A3 (en) | T cell receptors recognizing mutated p53 | |
| FI3393512T3 (fi) | Rsv f -proteiinin mutantteja | |
| JP2017538401A5 (enExample) | ||
| EP4609876A3 (en) | Anti-human papillomavirus 16 e7 t cell receptors | |
| JP2013537400A5 (enExample) | ||
| JP2018532382A5 (enExample) | ||
| JP2015532654A5 (enExample) | ||
| WO2007130455A3 (en) | Compositions and methods for treatment of non-hodgkins lymphoma | |
| JP2019522465A5 (enExample) | ||
| JP2016156828A5 (enExample) | ||
| JP2013519721A5 (enExample) | ||
| IL278014B2 (en) | Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use | |
| JP2012095652A5 (enExample) | ||
| JP2016526909A5 (enExample) | ||
| JP2010519176A5 (enExample) | ||
| WO2011028344A3 (en) | Interleukin-1 receptor antagonist compositions and methods of making and using same | |
| JP2015511637A5 (enExample) | ||
| TW201129379A (en) | Anti-Orai1 antigen binding proteins and uses thereof | |
| JP2009511000A5 (enExample) | ||
| RU2014150092A (ru) | Варианты ctla-4 |